Recap: Vanda Pharmaceuticals Q4 Earnings
Recap: Vanda Pharmaceuticals Q4 Earnings
Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) increased in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share increased 87.50% over the past year to $0.15, which beat the estimate of $0.14.
Revenue of $67,653,000 rose by 11.03% from the same period last year, which beat the estimate of $64,000,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
The upcoming fiscal year's revenue expected to be between $270,000,000 and $300,000,000.
How To Listen To The Conference Call
Date: Feb 10, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/3jdd3b89
Price Action
52-week high: $16.29
Company's 52-week low was at $7.12
Price action over last quarter: Up 40.22%
Company Description
Vanda Pharmaceuticals Inc is a biopharmaceutical company which is engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant (VLY-686), VTR-297, and VQW-765.
Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) increased in after-market trading after the company reported Q4 results.
的股份萬達製藥(納斯達克：VNDA)在該公司公佈第四季度業績後，盤後交易增加。
Quarterly Results
季度業績
Earnings per share increased 87.50% over the past year to $0.15, which beat the estimate of $0.14.
每股收益在過去一年中增長了87.50%，達到0.15美元，超過了0.14美元的預期。
Revenue of $67,653,000 rose by 11.03% from the same period last year, which beat the estimate of $64,000,000.
營收為67,653,000美元，較去年同期增長11.03%，超過預期的64,000,000美元。
Guidance
導向
Earnings guidance hasn't been issued by the company for now.
該公司目前尚未發佈盈利指引。
The upcoming fiscal year's revenue expected to be between $270,000,000 and $300,000,000.
下一財年的收入預計在2.7億美元至3億美元之間。
How To Listen To The Conference Call
如何收聽電話會議
Date: Feb 10, 2021
日期：2021年2月10日
Time: 04:30 PM
時間：下午4時30分
ET Webcast URL: https://edge.media-server.com/mmc/p/3jdd3b89
Price Action
價格行動
52-week high: $16.29
52周高點：16.29美元
Company's 52-week low was at $7.12
該公司52周低點為7.12美元
Price action over last quarter: Up 40.22%
上季度價格走勢：上漲40.22%
Company Description
公司描述
Vanda Pharmaceuticals Inc is a biopharmaceutical company which is engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant (VLY-686), VTR-297, and VQW-765.
萬達製藥公司是一家生物製藥公司，致力於藥物的開發和商業化，以滿足高度未得到滿足的醫療需求，並改善患者的生活。其產品組合包括Hetlioz、Fanapt、傳統型(VLY-686)、錄像機-297和VQW-765。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧